Resistant hypercalcaemia in metastatic parathyroid carcinoma

Medical Journal of Australia

Volumn 198, Issue 10, 2013, Pages 559-561

  Bowyer, Samantha E ^a   White, Alison M ^b   Ransom, David T ^a   Davidson, John A ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM; CINACALCET; CYCLOPHOSPHAMIDE; DACARBAZINE; DENOSUMAB; FLUOROURACIL; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE TUMOR; CANCER CHEMOTHERAPY; CASE REPORT; CHEMICAL ANALYSIS; CLAVICLE FRACTURE; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; INOPERABLE CANCER; LOADING DRUG DOSE; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; NECK DISSECTION; OUTCOME ASSESSMENT; PARATHYROID CARCINOMA; PARATHYROIDECTOMY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIMARY HYPERPARATHYROIDISM; SUBTOTAL THYROIDECTOMY; THORACOTOMY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; FATAL OUTCOME; HUMANS; HYPERCALCEMIA; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PARATHYROID NEOPLASMS; PLEURAL NEOPLASMS; RANK LIGAND; THYROID NEOPLASMS;

EID: 84878547627     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja12.11243     Document Type: Article

References (11)

1. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010; 11: 275-280.
2. Pittman KB, Olver IN, Koczwara B, et al. Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. Br J Cancer 2006; 95: 1309-1313.
3. Mezhir JJ, Melis M, Headley RC, et al. Successful palliation of hypercalcemia secondary to metastatic parathyroid cancer: an unusual indication for hepatic resection. J Hepatobiliary Pancreat Surg 2007; 14: 410-413.
4. Shane E. Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 485-493.
5. Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet hydrocholoride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 3803-3808.
6. Bukowski RM, Sheeler L, Cunningham J, Esselstyn C. Successful combination chemotherapy for metastatic parathyroid cancer. Arch Intern Med 1984; 144: 399-400.
7. Bradwell AR, Harvey TC. Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet 1999; 353: 370-373.
8. Burkiewicz JS, Scarpace SL, Bruce SP. Denosumab in osteoporosis and oncology. Ann Pharmacother 2009; 43: 1445-1455.
9. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139.
10. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-1132.
11. Falchetti A, Franchi A, Bordi C, et al. Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture. J Bone Miner Res 2005; 20: 410-418.